Review of the Current Knowledge on the Role of Stem Cell Transplantation in Neurorehabilitation

Kamelska-Sadowska, Anna M.; Wojtkiewicz, Joanna; Kowalski, Ireneusz M.

doi:10.1155/2019/3290894

Cited by 17 publications

(9 citation statements)

References 66 publications

(64 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stem cell transplantation therapy has become a hot topic in biomedical research, but its clinical application is still limited despite breakthroughs (59)(60)(61). currently, the greatest challenge facing ePc transplantation is how to improve in vivo survival, identify the outcomes of the transplanted cells and monitoring the effectiveness of the treatment (62).…”

Section: Discussionmentioning

confidence: 99%

MRI tracing of ultrasmall superparamagnetic iron oxide nanoparticle‑labeled endothelial progenitor cells for repairing atherosclerotic vessels in rabbits

Wei

Tan

et al. 2020

Mol Med Rep

View full text Add to dashboard Cite

Endothelial progenitor cells (EPCs) have been discovered to be relevant to the prognosis of cardiovascular diseases. Previous research has demonstrated that EPCs serve vital roles in the occurrence and development of atherosclerosis. Significant improvements have been made in MRI technology and in the experimental use of EPCs for therapeutic angiogenesis and vascular repair. Nevertheless, the migratory, adhesive, proliferative and angiogenic properties of EPCs remain unknown. The aims of the present study were to investigate the potential of using non-invasive monitoring with ultrasmall superparamagnetic iron oxide nanoparticle (USPION)-labeled endothelial progenitor cells (EPCs) after transplantation, and to assess the treatment outcomes in an atherosclerotic rabbit model. EPCs derived from rabbit peripheral blood samples were labeled with USPION-poly-l-lysine (USPION-PLL). The morphology, proliferation, adhesive ability and labeling efficiency of the EPCs were determined by optical and electron microscopy. Moreover, biological activity was assessed by flow cytometry. In addition, T2-weighted image fast spin-echo MRI was used to detect cell labeling. USPION content in the labeled EPCs was determined by Prussian blue staining and scanning electron microscopy. Rabbit atherosclerosis model was established using a high-fat diet. USPION-labeled EPCs were transplanted into rabbits, and in vivo MRI was performed 1 and 7 days after transplantation. It was found that EPCs cultured on Matrigel formed capillary-like structures, and expressed the surface markers CD133, CD31, CD34 and vascular endothelial growth factor receptor 2 (VEGFR2). The optimal USPION concentration was 32 µg/ml, as determined by adhesion and proliferation assays. It was identified that USPION-PLL nanoparticles were 10–20 nm in diameter. Histopathological analysis results indicated that 1 day after transplantation of the labeled EPCs, blue-stained granules were observed in the intima of vascular lesions in rabbit models after Prussian blue staining. Therefore, the present results suggest that USPION-labeled EPCs may play a role in repairing endothelial injury and preventing atherosclerosis in vivo .

show abstract

Section: Discussionmentioning

confidence: 99%

MRI tracing of ultrasmall superparamagnetic iron oxide nanoparticle‑labeled endothelial progenitor cells for repairing atherosclerotic vessels in rabbits

Wei

Tan

et al. 2020

Mol Med Rep

View full text Add to dashboard Cite

show abstract

“…The data for the use of HSCT in various refractory immune mediated neurological disorders have been accumulating over the past two decades, most notably for multiple sclerosis ( 99 , 100 ). Autologous stem cell transplantation has the advantage over allogenic transplantation in having lesser risk for graft vs. host disease.…”

Section: Hematopoetic Stem Cell Transplant (Hsct)mentioning

confidence: 99%

Novel Treatments in Myasthenia Gravis

2020

View full text Add to dashboard Cite

Myasthenia gravis (MG) is the prototypical autoimmune disorder caused by specific autoantibodies at the neuromuscular junction. Broad-based immunotherapies, such as corticosteroids, azathioprine, mycophenolate, tacrolimus, and cyclosporine, have been effective in controlling symptoms of myasthenia. While being effective in a majority of MG patients many of these immunosuppressive agents are associated with long-term side effects, often intolerable for patients, and take several months to be effective. With advances in translational research and drug development capabilities, more directed therapeutic agents that can alter the future of MG treatment have been developed. This review focuses on the aberrant immunological processes in MG, the novel agents that target them along with the clinical evidence for efficacy and safety. These agents include terminal complement C5 inhibitors, Fc receptor inhibitors, B cell depleting agents (anti CD 19 and 20 and B cell activating factor [BAFF)]inhibitors), proteosome inhibitors, T cells and cytokine based therapies (chimeric antigen receptor T [CART-T] cell therapy), autologous stem cell transplantation, and subcutaneous immunoglobulin (SCIG). Most of these new agents have advantages over conventional immunosuppressive treatment (IST) for MG therapy in terms of faster onset of action, favourable side effect profile and the potential for a sustained and long-term remission.

show abstract

“…The targeted regeneration of neuronal network resected during prostatectomy is at present out of range of current biotechnology (28). Based on available research data MSCs contributed to neuronal regeneration by supplying the healing environment with neuroprotective bioactive factors including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin (49). This effect was achieved by direct MSCs paracrine activity and indirectly by acting on the Schwann cells (50).…”

Section: Neuroregenerationmentioning

confidence: 99%

Tissue Engineering and Its Potential to Reduce Prostate Cancer Treatment Sequelae—Narrative Review

2021

View full text Add to dashboard Cite

Tissue engineering offers the possibility to overcome limitations of current management for postprostatectomy incontinence and ED. Developed in recent years biotechnological feasibility of mesenchymal stem cell isolation, in vitro cultivation and implantation became the basis for new cell-based therapies oriented to induce regeneration of adult tissue. The perspective to offer patients suffering from post-prostatectomy incontinence or erectile dysfunction minimal invasive one-time procedure utilizing autologous stem cell transplantation is desired management.

show abstract

Review of the Current Knowledge on the Role of Stem Cell Transplantation in Neurorehabilitation

Cited by 17 publications

References 66 publications

MRI tracing of ultrasmall superparamagnetic iron oxide nanoparticle‑labeled endothelial progenitor cells for repairing atherosclerotic vessels in rabbits

MRI tracing of ultrasmall superparamagnetic iron oxide nanoparticle‑labeled endothelial progenitor cells for repairing atherosclerotic vessels in rabbits

Novel Treatments in Myasthenia Gravis

Tissue Engineering and Its Potential to Reduce Prostate Cancer Treatment Sequelae—Narrative Review

Contact Info

Product

Resources

About